A new study reveals that the Fanconi anemia (FA) DNA repair pathway plays a critical, previously unappreciated role in restricting the development of MLL-rearranged (MLL-r) leukemia by preventing error-prone non-homologous end joining (NHEJ)-mediated genomic instability. Researchers demonstrated that when FA pathway components are lost or reduced, MLL-r leukemia cells exhibit hyperactive NHEJ, which accelerates malignant progression. By uncovering this specific vulnerability, the study identifies NHEJ blockade as a promising therapeutic strategy for high-risk MLL-r leukemia, showing that targeting this repair pathway can selectively impair leukemic cell survival while sparing normal hematopoietic stem cells.
Mixed lineage leukemia (MLL) rearrangements, which account for approximately 10 percent of acute leukemias, are generally associated with poor prognosis. While the FA pathway is well-characterized for its role in repairing DNA interstrand crosslinks and maintaining genomic integrity through homologous recombination, its interplay with MLL-r-driven leukemogenesis had remained unclear. By using murine models and human MLL-r leukemia cells, the researchers explored whether the FA pathway acts as a gatekeeper against genomic instability triggered by the replicative stress of oncogenic MLL fusion proteins.
The study found that FA gene haploinsufficiency, or the partial loss of key components such as Fanca or Fancd2, significantly exacerbates leukemia development in transgenic mice. Phenotypic analysis of these mice revealed an earlier onset of splenomegaly, lower platelet counts, and increased leukemia blasts in peripheral blood and bone marrow compared to their wild-type counterparts. Furthermore, flow cytometry showed significantly higher frequencies of leukemia stem cells in the FA-deficient models, demonstrating that a cooperative interaction between the defective DNA damage response pathway and MLL-r fusion drives faster disease progression.
Mechanistically, the loss of FA components leads to an accumulation of DNA damage and chromosomal instability. The researchers utilized immunofluorescence and reporter assays to assess DNA repair pathway preference, discovering that FA-deficient MLL-r cells preferentially utilize the error-prone NHEJ pathway for repair, whereas wild-type MLL-r cells rely more on the error-free homologous recombination pathway. Western blot analyses and proximity ligation assays indicated that the FA pathway functions by limiting the recruitment of NHEJ factors, such as KU70 and KU80, to the N-terminal region of the MLL fusion protein. AlphaFold3 structural modeling suggested that FA proteins may compete with NHEJ components for binding, thereby enforcing genomic stability.
To assess the therapeutic potential of this finding, the researchers tested the impact of selective NHEJ inhibitors, such as NU7026, in vitro and in vivo. Pharmacological inhibition of DNA-PKcs, a critical component of NHEJ, significantly impaired the expansion and survival of FA-deficient MLL-r leukemic cells. In patient-derived xenograft models using humanized mice, NU7026 treatment reduced the overall human leukemic burden and markedly prolonged survival in recipient mice with low FA gene expression. These results were consistent across various MLL-r translocation subtypes, establishing that reduced FA pathway activity serves as a biomarker for therapeutic sensitivity to NHEJ inhibition.
The study further investigated the translational utility of combination therapies, combining NHEJ inhibitors with agents currently used in the clinic, such as cytarabine (AraC) and the Menin inhibitor Ziftomenib (KO-539). In both FA-deficient murine models and human MLL-r leukemia cells, NHEJ inhibition exhibited synergistic cytotoxicity with AraC or KO-539, leading to significantly enhanced reductions in leukemia-initiating cell frequency and prolonged survival. Importantly, the research demonstrated that these combination regimens do not adversely affect the long-term function of normal human hematopoietic stem cells, suggesting a favorable therapeutic window.
An analysis of public transcriptomic datasets, including TARGET AML and BEAT AML, supported the clinical relevance of these findings by demonstrating an association between low FA gene expression and poor prognosis in patients with monocytic AML, a subtype linked to MLL rearrangements. Furthermore, computational models predicted higher sensitivity to PARP inhibition in these FA-low samples, aligning with the broader principle that targeting synthetic lethal dependencies can exploit genetic defects in cancer cells. These data reinforce the potential of utilizing NHEJ blockade as a targeted strategy to address the high-risk nature of MLL-r leukemia.
The researchers also addressed the structural basis of this regulatory mechanism by modeling the interactions between the MLL N-terminal domain, FANCD2, and the NHEJ machinery. Their results suggested that FANCD2 and KU70/KU80 compete for access to the same interaction interface on MLL-N, providing a molecular basis for the shift in repair pathway usage. This context-dependent suppression of error-prone repair appears exclusive to MLL-r leukemia, as it was not observed in non-MLL-r human cell lines, further underscoring the specificity of this genomic safeguarding mechanism in MLL-driven disease.
Despite the insights provided, the study noted that while partial loss of FA genes is sufficient to accelerate leukemia, complete loss is embryonically lethal in MLL-r mice, highlighting the essential nature of the FA pathway. The findings illustrate a paradigm where MLL-r leukemias exploit the dysregulation of DNA repair pathways to drive their own progression, simultaneously creating a vulnerability that can be targeted. The researchers concluded that identifying this mechanistic role of the FA pathway in limiting NHEJ-mediated mutagenesis provides a strong rationale for developing NHEJ-targeted interventions as a durable approach to eradicating MLL-r leukemia.
To trace how Fanconi anemia deficiency reshapes cell growth over time, researchers isolated lineage-depleted hematopoietic stem and progenitor cells from mice lacking Fanca, Fancc, or Fancd2 and introduced an MLL-AF9 retroviral construct expressing green fluorescent protein. During the initial two weeks of ex vivo culture, wild-type cells transduced with MLL-AF9 proliferated more quickly than their Fanconi anemia-deficient counterparts. However, after two weeks of continuous culture, the mutant populations underwent a pronounced growth surge, displaying marked reductions in apoptotic cell fractions alongside heightened Ki67 nuclear expression at day twenty. When evaluated in methylcellulose colony-forming unit assays, these transformed Fanconi-deficient progenitors formed substantially larger colonies and generated higher overall colony numbers than control cells. This clonogenic advantage was sustained across repeated secondary and tertiary plating cycles, confirming that the loss of Fanconi pathway integrity directly enhances the self-renewal capacity and sustained proliferative potential of leukemic progenitor populations.
The investigative team also examined the biochemical cascades governing DNA damage signaling by evaluating specific post-translational modifications in response to the crosslinking agent mitomycin C. While control cells cleared inhibitory tyrosine-142 phosphorylation on histone H2AX and stimulated protective downstream checkpoint phosphorylation at Chk2-T68, p53-S15, and ATM-S1981, cells lacking Fanconi components retained high H2AX-Y142 phosphorylation and failed to induce normal checkpoint activation. Neutral single-cell gel electrophoresis confirmed this repair breakdown, showing significantly longer comet tail moments in Fanconi-deficient MLL-AF9 cells relative to wild-type controls. Furthermore, metaphase chromosome spreads prepared following colcemid arrest revealed elevated frequencies of chromosomal breaks, dicentric chromosomes, and fragmented segments. When double-strand break sites were examined by immunofluorescence in synchronized cells, Fanconi-deficient progenitors showed preferential co-localization of gamma-H2AX with the non-homologous end joining marker 53BP1 rather than the homologous recombination marker RAD51, accompanied by elevated baseline levels of KU70 and KU80 proteins.
To establish whether this synthetic vulnerability occurs widely across distinct genetic backgrounds, the authors extended their testing to multiple established human leukemia lines. Silencing FANCD2 or FANCA enhanced sensitivity to the DNA-PKcs inhibitor NU7026 in MLL-rearranged acute myeloid leukemia lines THP-1 and MV4-11, as well as in the MLL-AF4-positive acute lymphoblastic leukemia line RS4;11. Similar hypersensitivity emerged when treating cells with NU1025, an inhibitor targeting PARP1. Crucially, this therapeutic susceptibility did not develop in non-rearranged HL-60 or MOLT-4 cells, nor did it appear in MLL-negative monocytic leukemia lines OCI-AML3 or U937, demonstrating that the vulnerability depends specifically on the presence of an MLL fusion. To verify physical association while ruling out artificial bridging mediated by nucleic acid fragments, the team pre-treated cell lysates with DNase I before performing co-immunoprecipitation experiments, confirming direct enhancement of KU70 and KU80 association with the retained N-terminal segment of MLL exclusively upon Fanconi pathway knockdown.
The evaluation of translational safety focused on hematopoietic recovery using sublethally irradiated NSGS mice engrafted with normal human umbilical cord blood CD34-positive cells. Following combination regimens delivering NU7026 alongside cytarabine or the Menin inhibitor KO-539, recipients experienced an expected, transient decline in total human CD45-positive engraftment, mature hematopoietic progenitors, and immature CD34-positive, CD38-negative stem cell fractions at one month post-treatment. By three months, however, these normal donor cell populations fully recovered to levels comparable to vehicle-treated controls, establishing that the dual-targeting strategy spares long-term repopulating human stem cells. The therapeutic protocols in xenograft models involved carefully timed administration, delivering daily intraperitoneal NU7026 injections at twenty milligrams per kilogram body weight across four consecutive days, while oral KO-539 or intraperitoneal cytarabine were administered over seven days with four-hour dosing intervals between distinct agents, providing durable anti-leukemic suppression without causing intolerable systemic hematologic exhaustion.
Subject of Research: Oncology and DNA Repair Mechanisms in MLL-Rearranged Leukemia
Article Title: The Fanconi anemia pathway restrains MLL-rearranged leukemogenesis through suppressing non-homologous end joining-mediated genomic instability
Article References: Xu, J., Sund, L. M., Wolff, E. V., Zhu, A. Z., Wang, R., Gao, Z., Ito, S., & Du, W. (2026). The Fanconi anemia pathway restrains MLL-rearranged leukemogenesis through suppressing non-homologous end joining-mediated genomic instability. Nature Communications, 17(1), Article 10384. https://doi.org/10.1038/s41467-026-77335-0
Image Credits: AI Generated
DOI: 10.1038/s41467-026-77335-0
Keywords: Fanconi anemia, MLL-rearranged leukemia, DNA damage response, Non-homologous end joining, Genomic instability, Leukemogenesis, Targeted therapy, Synthetic lethality, NHEJ inhibition, FANCD2, DNA-PKcs, Hematological cancer, Acute myeloid leukemia, Acute lymphoblastic leukemia, Translational medicine, Menin inhibitor, Cytarabine, Repair pathway choice

